SUTENT for Renal cell carcinoma: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 247 adverse event reports in the FDA FAERS database where SUTENT was used for Renal cell carcinoma.
Most Reported Side Effects for SUTENT
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Disease progression | 226 | 18.9% | 84 | 30 |
| Death | 225 | 18.8% | 225 | 37 |
| Diarrhoea | 164 | 13.7% | 23 | 40 |
| Fatigue | 140 | 11.7% | 12 | 23 |
| Nausea | 119 | 9.9% | 19 | 36 |
| Decreased appetite | 78 | 6.5% | 15 | 25 |
| Vomiting | 73 | 6.1% | 20 | 30 |
| Asthenia | 67 | 5.6% | 13 | 27 |
| Oral pain | 66 | 5.5% | 10 | 10 |
| Dysgeusia | 63 | 5.3% | 6 | 9 |
| Hypertension | 59 | 4.9% | 6 | 20 |
| Stomatitis | 58 | 4.8% | 8 | 12 |
| Pain in extremity | 53 | 4.4% | 9 | 9 |
| Renal cell carcinoma | 53 | 4.4% | 28 | 8 |
| Weight decreased | 51 | 4.3% | 3 | 12 |
Other Indications for SUTENT
Renal cancer (272)
Metastatic renal cell carcinoma (157)
Gastrointestinal stromal tumour (83)
Neoplasm malignant (52)
Renal cancer metastatic (45)
Pancreatic neuroendocrine tumour (19)
Pancreatic carcinoma (12)
Clear cell renal cell carcinoma (10)
Malignant urinary tract neoplasm (9)
Thyroid cancer (8)
Other Drugs Used for Renal cell carcinoma
CABOZANTINIB S-MALATE (9,156)
NIVOLUMAB (6,514)
LENVATINIB (3,849)
PEMBROLIZUMAB (3,027)
SUNITINIB MALATE (2,926)
PAZOPANIB (2,799)
IPILIMUMAB (2,585)
AXITINIB (2,447)
EVEROLIMUS (1,573)
TIVOZANIB (1,258)